Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
FDA designation will facilitate development and expedited review of company's lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2020 Results - Earnings Call Transcript
03:19pm, Wednesday, 03'rd Mar 2021
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2020 Results - Earnings Call Transcript
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
07:00am, Wednesday, 03'rd Mar 2021
- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krab
Gain Therapeutics Aims For $40 Million IPO
03:31pm, Thursday, 25'th Feb 2021
Gain Therapeutics has filed to raise $40 million in a U.S. IPO.
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
07:00am, Friday, 19'th Feb 2021
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
- Phase 1/2 trial expected to commence in first half of 2021
– Second Product Candidate Expected to Enter Clinic in First Half of 2021
PASG Stock Price Fell 13.19%: Why It Happened
12:29pm, Saturday, 23'rd Jan 2021
The stock price of Passage Bio Inc (NASDAQ: PASG) as it went from a previous close of $22.82 to $19.81 fell 13.19%. This is why it happened.
Here's Why Shares of Passage Bio Dropped Today
02:22pm, Friday, 22'nd Jan 2021
A secondary offering will dilute shareholders.
Passage Bio Announces Pricing of Public Offering
07:48pm, Thursday, 21'st Jan 2021
PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system d
Passage Bio Announces Launch of Proposed Public Offering
04:06pm, Tuesday, 19'th Jan 2021
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system d
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
08:00am, Thursday, 07'th Jan 2021
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and
Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 04'th Jan 2021
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021
Passage Bio Announces Gene Therapy Manufacturing Research and Development Site
08:00am, Wednesday, 16'th Dec 2020
- Company invests to build in-house capabilities to support advancement of pipeline -
